- Home
- ITIC vs ESPR Comparison
ITIC vs ESPR Comparison
Compare ITIC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- ESPR
- Stock Information
- Founded
- ITIC 1972
- ESPR 2008
- Country
- ITIC United States
- ESPR United States
- Employees
- ITIC N/A
- ESPR N/A
- Industry
- ITIC Specialty Insurers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- ESPR Health Care
- Exchange
- ITIC Nasdaq
- ESPR Nasdaq
- Market Cap
- ITIC 423.0M
- ESPR 410.2M
- IPO Year
- ITIC N/A
- ESPR 2013
- Fundamental
- Price
- ITIC $224.28
- ESPR $1.82
- Analyst Decision
- ITIC
- ESPR Buy
- Analyst Count
- ITIC 0
- ESPR 6
- Target Price
- ITIC N/A
- ESPR $7.25
- AVG Volume (30 Days)
- ITIC 10.1K
- ESPR 3.3M
- Earning Date
- ITIC 02-13-2025
- ESPR 03-04-2025
- Dividend Yield
- ITIC 6.90%
- ESPR N/A
- EPS Growth
- ITIC 43.49
- ESPR N/A
- EPS
- ITIC 16.43
- ESPR N/A
- Revenue
- ITIC $258,298,000.00
- ESPR $295,451,000.00
- Revenue This Year
- ITIC N/A
- ESPR $186.86
- Revenue Next Year
- ITIC N/A
- ESPR $9.41
- P/E Ratio
- ITIC $14.11
- ESPR N/A
- Revenue Growth
- ITIC 15.03
- ESPR 187.12
- 52 Week Low
- ITIC $146.41
- ESPR $1.58
- 52 Week High
- ITIC $290.40
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ITIC 44.36
- ESPR 38.40
- Support Level
- ITIC $220.01
- ESPR $1.82
- Resistance Level
- ITIC $233.74
- ESPR $1.91
- Average True Range (ATR)
- ITIC 5.38
- ESPR 0.09
- MACD
- ITIC 0.93
- ESPR 0.02
- Stochastic Oscillator
- ITIC 37.02
- ESPR 47.83
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.